20/20 Biolabs, Inc. received a notification from Nasdaq on September 3, 2026, indicating non-compliance with the $2,500,000 stockholders' equity requirement under Listing Rule 5550(b)(1). The company's Form 10-Q for the period ended June 30, 2026, reported stockholders’ equity of $1,620,700. Nasdaq has granted the company 45 calendar days to submit a plan to regain compliance; if accepted, an extension of up to 180 calendar days may be granted. Failure to comply by January 13, 2027, would disqualify the company from a second compliance period for its previously cited bid price deficiency. The company operates in the biotechnology industry, focusing on laboratory diagnostics and research products.

20/20 Biolabs reported second quarter 2026 financial results with total revenue increasing 36.5% to $0.7 million and gross profit rising 86.6% to $0.3 million, driven by a 47.1% year-over-year increase in OneTest™ revenue to $0.7 million. Gross margin expanded to 41.7% from 30.5%, while the net loss widened to $1.5 million due to operating expenses and non-cash charges. The company strengthened its balance sheet by raising $6.0 million in Series E preferred financing during the first half of 2026 and eliminating all convertible note debt through conversion into preferred stock. Cash reserves grew to $4.5 million as of June 30, 2026. Additionally, the company entered a standstill agreement with Streeterville regarding potential conversions of its Series E shares. The company operates in the healthcare diagnostics industry, developing AI-powered blood tests for early cancer detection.

20/20 Biolabs, Inc. entered into a 120-day standstill agreement with Streeterville Capital, LLC on July 16, 2026, preventing Streeterville from converting series E convertible preferred stock into common stock unless the stock price is at least 10% above the Nasdaq Minimum Price. Additionally, the company received a Nasdaq delisting notice on July 17, 2026, due to following the $1.00 closing bid price requirement for 30 consecutive business days. The company has until January 13, 2027, to regain compliance. 20/20 Biolabs, Inc. is a biotechnology company that provides laboratory testing services.